Studies have suggested that patients with the BRAF V600E mutation should be overtreated to some extent47, because BRAF mutations are an independent risk factor for lymph node metastasis and are closely related to tumor size and invasiveness48-57. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.